AMGN compared with RLAY: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

RLAYRelay Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

RLAYRelay Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

AMGNAmgen Inc

460.67· pre 474.00· delayed

Mkt cap$249.4BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

RLAYRelay Therapeutics, Inc.

17.43· pre 17.43· delayed

Pre-marketNov 4 '26delayed

Mkt cap$3.8BRevenue$350,000Q2 FY26Revenue—

Compare

Pre-marketNov 4 '26delayed

AMGNAmgen Inc

RLAYRelay Therapeutics, Inc.

460.67pre 474.00delayed

Price

17.43pre 17.43delayed

$249.4B

Mkt cap

$3.8B

Q3 FY26$10.4B

Revenue

$350,000Q2 FY26

FY25$36.8B

Revenue

—

AMGN460.67vsRLAY17.43Pre-marketNov 4 '26delayed

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

RLAY: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

AMGN, solidRLAY, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only RLAY 3

—D.E. Shaw Researchunlistedsupplier

—Elevar Therapeuticsunlistedcustomer

—Genentechunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR